MedWatch

New Novo Nordisk treatment targets 25% weight loss

After positive phase II results from a combination trial, Novo Nordisk now believes its weekly treatment Cagrisema can provide up to 25% weight loss for people with severe obesity without diabetes.

Martin Holst Lange, executive vice president of development, Novo Nordisk | Photo: Novo Nordisk / PR

Novo Nordisk’s weekly combination treatment Cagrisema could generate more than 25% weight loss for people with severe obesity without diabetes, says Martin Holst Lange, executive vice president of development at the firm.

This comes after promising phase II results were released on Monday, which showed better blood sugar effects on people with type 2 diabetes and better weight loss effects among people with obesity and severe obesity than Novo’s current bestseller, semaglutide. The patent on semaglutide expires in the early 2030s.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs